The Battle Among Channels for Marketing Pharmaceuticals: UpScript, Pharmacy Benefit Managers, and Direct-to-Consumer Sales Custom Case Solution & Analysis

1. Evidence Brief

Financial Metrics

• PBM Market Concentration: Three large Pharmacy Benefit Managers (PBMs) control approximately 80 percent of the total prescription volume in the United States.
• UpScript Revenue Model: The platform charges a flat fee for the medical consultation, typically ranging from 20 to 50 dollars, plus the cost of the medication.
• Marketing Spend: Pharmaceutical companies spend over 6 billion dollars annually on direct-to-consumer advertising, yet conversion at the pharmacy counter remains a significant leak in the sales funnel.
• Patient Out-of-Pocket Costs: High-deductible health plans have increased patient sensitivity to drug prices, with some out-of-pocket costs for tier-three drugs exceeding 200 dollars per month.
• Abandonment Rates: Prescription abandonment increases by 25 percent when the out-of-pocket cost reaches 50 dollars and exceeds 50 percent when costs top 200 dollars.

Operational Facts

• UpScript Workflow: Patient completes an online assessment; a licensed physician reviews the file; if approved, the prescription is sent to a partner pharmacy for home delivery.
• PBM Function: PBMs manage formularies, negotiate rebates with manufacturers, and process claims for insurance providers.
• Distribution Channels: Traditional retail pharmacy, mail-order pharmacy via PBMs, and emerging direct-to-patient telehealth platforms.
• Regulatory Compliance: Telehealth prescribing must adhere to state-specific medical board regulations regarding the physician-patient relationship.

Stakeholder Positions

• Peter Ax (UpScript CEO): Asserts that the traditional PBM-led model creates unnecessary friction and that manufacturers need a direct path to the consumer to ensure medication adherence.
• Pharma Manufacturers: Caught between the necessity of PBM formulary access and the desire to own the patient relationship and reduce prescription abandonment.
• PBM Executives: Maintain that they are the primary defense against rising drug prices through scale-based negotiation.
• Patients: Increasingly seeking convenience and price transparency, similar to other retail experiences.

Information Gaps

• Specific unit economics for pharmaceutical manufacturers when bypassing PBMs via UpScript versus traditional retail.
• Long-term patient retention rates on telehealth platforms compared to traditional chronic care models.
• Detailed legal implications of PBM contract clauses that may penalize manufacturers for redirecting volume to DTC channels.

2. Strategic Analysis

Core Strategic Question

• Should pharmaceutical manufacturers aggressively shift volume to direct-to-consumer (DTC) telehealth channels to bypass PBM gatekeepers, or will the resulting PBM retaliation and high patient acquisition costs outweigh the benefits of direct distribution?

Structural Analysis

The pharmaceutical distribution value chain is undergoing a structural shift driven by the following factors:

• Buyer Power: PBMs exert extreme bargaining power through formulary exclusion. If a drug is not on the preferred list, it is effectively invisible to the insured population.
• Disintermediation: Platforms like UpScript remove the physical pharmacy and the PBM claim process from the transaction, shifting the power back to the manufacturer and the prescribing physician.
• Threat of Substitutes: Telehealth-driven DTC is a substitute for the traditional doctor-office-to-retail-pharmacy journey. It addresses the Jobs-to-be-Done of convenience and price certainty.

Strategic Options

Preliminary Recommendation

Pursue the Hybrid Strategic Access model. Manufacturers should utilize UpScript as a secondary channel to capture the 50 percent of patients who abandon prescriptions due to high out-of-pocket costs or PBM denials. This allows the manufacturer to maintain broad insurance coverage while providing a safety net for lost revenue. This path is preferred because it minimizes the risk of total PBM exclusion while building the internal capability to manage direct patient relationships.

3. Implementation Roadmap

Critical Path

• Month 1: Identify high-abandonment drug candidates within the portfolio, focusing on those with tier-three status or high prior-authorization requirements.
• Month 2: Establish legal and compliance framework for state-by-state telehealth prescribing and direct-to-patient shipping.
• Month 3: Integrate digital marketing assets with the UpScript platform to ensure a seamless transition from advertisement to consultation.
• Month 4: Launch pilot program for a single therapeutic area to measure conversion rates and patient lifetime value.

Key Constraints

• Regulatory Variance: Telehealth laws vary significantly by state, particularly regarding the necessity of a synchronous video visit versus an asynchronous questionnaire.
• PBM Retaliation: Large PBMs may view DTC shifts as a breach of preferred status agreements, leading to higher tiering or total exclusion in the next contracting cycle.
• Patient Acquisition Cost: The cost to drive a patient to a specific DTC landing page may exceed the margin generated from the initial prescription.

Risk-Adjusted Implementation Strategy

The strategy will follow a phased rollout to mitigate the risk of PBM conflict. Initially, the DTC channel will not be advertised on primary brand websites. Instead, it will be used as a recovery tool for patients who have already been denied coverage. This targeted approach ensures that the manufacturer is only bypassing the PBM when the PBM has already failed to facilitate the sale. Contingency plans include a 20 percent budget buffer for legal challenges and a modular marketing spend that can be throttled based on real-time acquisition costs.

4. Executive Review and BLUF

BLUF

Manufacturers must adopt a direct-to-consumer distribution channel via platforms like UpScript to stop the 50 percent revenue leakage caused by PBM-induced pharmacy abandonment. The traditional model is broken for high-cost and lifestyle medications. By implementing a hybrid channel strategy, the company can capture denied claims without triggering a full-scale war with PBMs. Success depends on precise targeting of patients who have already encountered friction in the traditional system. We must move now to secure the direct patient relationship before PBMs launch their own competing telehealth front-ends.

Dangerous Assumption

The analysis assumes that PBMs will remain passive as volume shifts to DTC channels. In reality, PBMs have the data to identify when a manufacturer is redirecting patients and can use formulary exclusion as a blunt instrument to force compliance across the entire manufacturer portfolio.

Unaddressed Risks

• Data Privacy and Security: Managing patient health information (PHI) directly increases the surface area for data breaches and associated regulatory fines. Probability: Moderate. Consequence: High.
• Physician Backlash: Traditional prescribing physicians may view DTC telehealth platforms as a threat to their practice or a dilution of the standard of care. Probability: High. Consequence: Moderate.

Unconsidered Alternative

The team did not consider a white-label PBM strategy. Instead of bypassing PBMs, the manufacturer could partner with a smaller, transparent-pass-through PBM to create a custom network that offers lower costs to patients while still utilizing the traditional pharmacy infrastructure. This would provide the benefits of the DTC model with less regulatory and retaliatory risk.

Verdict